Effectiveness of an intervention to improve the vaccination coverage against Streptococcus pneumoniae in patients with chronic kidney disease
Pneumococcal vaccination is recommended for chronic kidney disease (CKD) patients. We evaluated the impact of implementing a hospital vaccine consultation on their vaccination coverages. A sample was drawn from consecutive cases referred to our clinic between November 2014 and June 2018. 101 patient...
Saved in:
Main Authors: | , |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_bd54e2272a9a42e9a1bd12ad6b2719f9 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Ignacio Hernández-García |e author |
700 | 1 | 0 | |a Carlos Aibar-Remón |e author |
245 | 0 | 0 | |a Effectiveness of an intervention to improve the vaccination coverage against Streptococcus pneumoniae in patients with chronic kidney disease |
260 | |b Taylor & Francis Group, |c 2021-01-01T00:00:00Z. | ||
500 | |a 2164-5515 | ||
500 | |a 2164-554X | ||
500 | |a 10.1080/21645515.2020.1759975 | ||
520 | |a Pneumococcal vaccination is recommended for chronic kidney disease (CKD) patients. We evaluated the impact of implementing a hospital vaccine consultation on their vaccination coverages. A sample was drawn from consecutive cases referred to our clinic between November 2014 and June 2018. 101 patients were analyzed: 4 had received the pneumococcal conjugated vaccine 13-valent at the time of the first appointment, whereas 93 had received it after being seen (RR (95%-CI) = 23.3 (8.88-60.85)). Moreover, 5 had received the pneumococcal polysaccharide vaccine 23-valent at the time of the first appointment, whereas 90 had received it after being seen (RR (95%-CI) = 18.0 (7.64-42.42)). Implementing a hospital-based vaccine consultation represents an effective intervention to improve pneumococcal vaccination coverage in these patients. | ||
546 | |a EN | ||
690 | |a vaccination coverage | ||
690 | |a pneumococcal vaccines | ||
690 | |a renal insufficiency | ||
690 | |a chronic | ||
690 | |a referral and consultation | ||
690 | |a Immunologic diseases. Allergy | ||
690 | |a RC581-607 | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 17, Iss 1, Pp 170-172 (2021) | |
787 | 0 | |n http://dx.doi.org/10.1080/21645515.2020.1759975 | |
787 | 0 | |n https://doaj.org/toc/2164-5515 | |
787 | 0 | |n https://doaj.org/toc/2164-554X | |
856 | 4 | 1 | |u https://doaj.org/article/bd54e2272a9a42e9a1bd12ad6b2719f9 |z Connect to this object online. |